Abstract

Case Report

Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: A Significant Cause of End-Stage Kidney Disease in Children

Bouchoual M*, Dadi K, El Khand A, El Ouazzani M, Anibar S, Jabrane M and Arrayhani M

Published: 29 January, 2025 | Volume 9 - Issue 1 | Pages: 020-023

Introduction: Membranoproliferative glomerulonephritis (MPGN) is a significant cause of glomerulopathy and chronic kidney disease (CKD) or end-stage renal disease (ESRD) in children. The deposition of circulating immune complexes in the glomerulus and abnormal activation of the alternative complement pathway is believed to trigger the disease. However, there is limited knowledge regarding the optimal treatment and prognosis for children with immune complex-associated MPGN (IC-MPGN) and C3 glomerulopathy (C3G).
Case report: We report the case of a 14-year-old child admitted for rapidly progressive glomerulonephritis with anuria managed on haemodialysis. The kidney biopsy showed an appearance compatible with MPGN on light microscopy, with immunoglobulin and complement C3 deposits on direct immunofluorescence. The prognosis was poor, with rapid progression to ESRD despite treatment combining corticosteroid therapy and immunosuppressants.
Discussion and conclusion: Evaluating the effectiveness of different therapeutic approaches for MPGN in children is challenging due to the small sample sizes and the short duration of the published controlled studies. As a result, it is crucial to conduct more comprehensive trials that focus on both prognosis and treatment options.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001147 Cite this Article Read Full Article PDF

Keywords:

Membranoproliferative glomerulonephritis; Chronic Kidney disease; Children

References

  1. Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol. 2015;11:14–22. Available from: https://doi.org/10.1038/nrneph.2014.217
  2. Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, et al. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/ immune complex-mediated membranoproliferative GN. J Am Soc Nephrol. 2018;29:283–294. Available from: https://doi.org/10.1681/asn.2017030258
  3. Kovala M, Seppälä M, Räisänen-Sokolowski A, Meri S, Honkanen E, Kaartinen K. Diagnostic and prognostic comparison of immune-complex-mediated membranoproliferative glomerulonephritis and C3 glomerulopathy. Cells. 2023;12:712. Available from: https://doi.org/10.3390/cells12050712
  4. Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, et al. Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Mol Immunol. 2016;71:131–142. Available from: https://doi.org/10.1016/j.molimm.2016.01.010
  5. Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, et al. Unraveling the molecular mechanisms underlying complement dysregulation by nephritic factors in C3G and IC-MPGN. Front Immunol. 2018;9:2329. Available from: https://doi.org/10.3389/fimmu.2018.02329
  6. Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant. 2012;27:4288–4294. Available from: https://doi.org/10.1093/ndt/gfs288
  7. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis– a new look at an old entity. N Engl J Med. 2012;366:1119–1131. Available from: https://doi.org/10.1056/nejmra1108178
  8. Fakhouri F, Le Quintrec M, Frémeaux-Bacchi V. Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. Kidney Int. 2020;98:1135–1148. Available from: https://doi.org/10.1016/j.kint.2020.05.053
  9. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82:454–464. Available from: https://doi.org/10.1038/ki.2012.63
  10. Ueda C, Horinouchi T, Inoki Y, Ichikawa Y, Tanaka Y, Kitakado H, et al. Clinical characteristics and outcomes of immune‑complex membranoproliferative glomerulonephritis and C3 glomerulopathy in Japanese children. Pediatr Nephrol. 2024;39:2679–2689. Available from: https://doi.org/10.1007/s00467-024-06377-7
  11. Riedl M, Thorner P, Licht C. C3 glomerulopathy. Pediatr Nephrol. 2017;32:43–57. Available from: https://doi.org/10.1007/s00467-015-3310-4
  12. Licht C, Schlötzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II – genetically determined by defective complement regulation? Pediatr Nephrol. 2007;22:2–9. Available from: https://doi.org/10.1007/s00467-006-0299-8
  13. Alchi B, Jayne D. Membranoproliferative glomerulonephritis. Pediatr Nephrol. 2010;25:1409–1418. Available from: https://doi.org/10.1007/s00467-009-1322-7
  14. Levin A. Management of membranoproliferative glomerulonephritis: evidence-based recommendations. Kidney Int. 1999;70:S41–S46. Available from: https://doi.org/10.1046/j.1523-1755.1999.07006.x
  15. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone—a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992;6:123–130. Available from: https://doi.org/10.1007/bf00866289
  16. Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994;67:59–6. Available from: https://doi.org/10.1159/000187889
  17. Schubart A, Anderson K, Mainolfi N, Sellner H, Ehara T, Adams CM, et al. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases. Proc Natl Acad Sci U S A. 2019;116:7926–7931. Available from: https://doi.org/10.1073/pnas.1820892116
  18. Bomback AS, Kavanagh D, Vivarelli M, Meier M, Wang Y, Webb NJA, et al. Alternative complement pathway inhibition with iptacopan for the treatment of C3 glomerulopathy—study design of the APPEAR-C3G trial. Kidney Int Rep. 2022;7:2150–2159. Available from: https://doi.org/10.1016/j.ekir.2022.07.004
  19. Schubart A, Flohr S, Junt T, Eder J. Low-molecular weight inhibitors of the alternative complement pathway. Immunol Rev. 2023;313:339–357. Available from: https://doi.org/10.1111/imr.13143
  20. Patry C, Webb NJA, Feißt M, Krupka K, Becker J, Bald M, et al. Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network. Pediatr Nephrol. 2024;39:3569–3580. Available from: https://link.springer.com/article/10.1007/s00467-024-06476-5

Figures:

Figure 1

Figure 1

Figure 1

Figure 2

Figure 1

Figure 3

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?